targets and emerging therapies for schizophrenia

Download Book Targets And Emerging Therapies For Schizophrenia in PDF format. You can Read Online Targets And Emerging Therapies For Schizophrenia here in PDF, EPUB, Mobi or Docx formats.

Targets And Emerging Therapies For Schizophrenia

Author : Jeffrey S. Albert
ISBN : 9781118309407
Genre : Medical
File Size : 52. 29 MB
Format : PDF, ePub, Docs
Download : 497
Read : 1157

Download Now Read Online

New and emerging directions in pharmaceutical research to better treat schizophrenia Although the dopamine hypothesis has been the cornerstone of schizophrenia therapeutics, it is clear that dopamine-based approaches do not treat all aspects of the disease. Moreover, many schizophrenia patients fail to respond to current antipsychotics. Integrating chemistry, biology, and pharmacology, this book explores emerging directions in pharmaceutical research for drug targeting and discovery in order to find more effective treatments for schizophrenia, one of the most serious and widespread psychiatric diseases. Targets and Emerging Therapies for Schizophrenia presents the basics of schizophrenia, drug targets for the disease, and potential new drugs and therapeutics. It begins with a discussion of prevalence and etiology. Then, it describes therapies such as dopamine agonists and phosphodiesterase (PDE) inhibitors as well as growing research aimed at addressing untreated symptoms. Next, the authors discuss receptor modulators, inhibitors, and targeting strategies for drug discovery. Both the neurobiological and chemical aspects of all major pharmacological targets are examined. With contributions from an international team of pioneering pharmaceutical researchers, this book compiles the current knowledge in the field, setting the stage for new breakthroughs in the treatment of schizophrenia. Targets and Emerging Therapies for Schizophrenia: Provides a comprehensive resource for neuro-drug discovery and the development of molecular targets for schizophrenia treatment Draws from chemistry, biology, and pharmacology for more effective drug targeting and discovery Explores a wide range of receptors and molecular targets, including dopamine, PDEs, and neuropeptides With Targets and Emerging Therapies for Schizophrenia as their guide, drug discovery and development scientists have the information they need to advance their own research so that new, more effective treatments for schizophrenia will soon be a reality.

Novel Antischizophrenia Treatments

Author : Mark A. Geyer
ISBN : 9783642257582
Genre : Medical
File Size : 48. 51 MB
Format : PDF, ePub, Mobi
Download : 770
Read : 1168

Download Now Read Online

This volume tries to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. The volume concentrates on reviewing the ongoing research attempting to identify novel treatments for the cognitive deficits and negative symptoms of schizophrenia, which are not treated adequately by current antipsychotic medications.

Current Antipsychotics

Author : Gerhard Gross
ISBN : 9783642257612
Genre : Medical
File Size : 76. 35 MB
Format : PDF, Kindle
Download : 463
Read : 924

Download Now Read Online

Six decades after the serendipitous discovery of chlorpromazine as an antipsychotic and four decades after the launch of clozapine, the first atypical or second generation antipsychotic, psychopharmacology has arrived at an important crossroad. It is clear that pharmacological research and pharmaceutical development must now focus on complementary or even alternative mechanisms of action to address unmet medical needs, i.e. poorly treated domains of schizophrenia, improved acceptance by patients, better adherence to medication, safety in psychoses in demented patients, and avoiding cardiac and metabolic adverse effects. The first completely novel mechanisms evolving from our insights into the pathophysiology of psychotic disorders, especially the role of glutamatergic mechanisms in schizophrenia, are now under development, and further principles are on the horizon. This situation, in many respects similar to that when the initial second-generation antipsychotics became available, can be rewarding for all. Preclinical and clinical researchers now have the opportunity to confirm their hypotheses and the pharmaceutical industry may be able to develop really novel classes of therapeutics. When we were approached by the publishers of the Handbook of Experimental Pharmacology to prepare a new volume on antipsychotics, our intention was to capture both, the accumulated preclinical and clinical knowledge about current antipsychotics as well as prospects for new and potentially more specific antischizophrenia principles. These efforts should be based on the pathophysiology of the diseases and the affected neurotransmitter systems. Since preclinical research on antipsychotic compounds is only reliable when intimately linked through translational aspects to clinical results, we decided to include clinical science as well. It turned out that that this endeavor could not be covered by a single volume. We thank the editorial board and the publishers for supporting our decision to prepare two volumes: Current Antipsychotics and Novel Antischizophrenia Treatments. These topics cannot really be separated from one another and should be seen as a composite entity despite the somewhat arbitrary separation of contributions into two volumes. The continuing challenges of developing improved and safer antipsychotic medications remain of concern and are discussed in the first volume. The new opportunities for the field to develop and license adjunctive treatments for the negative symptoms and cognitive deficits that are treated inadequately by existing compounds have been incentivized recently and provide the focus for the second volume. We hope these collective contributions will facilitate the development of improved treatments for the full range of symptomatology seen in the group of schizophrenias and other major psychotic disorders. Gerhard Gross, Ludwigshafen, Germany Mark A. Geyer, La Jolla, CA This volume will try to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters will also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. Non-schizophrenia indications will be covered to some extent, but not exhaustively.


Author : Varghese John
ISBN : 0470594071
Genre : Medical
File Size : 66. 96 MB
Format : PDF, ePub
Download : 332
Read : 998

Download Now Read Online

BACE inhibitors and their use in the treatment of Alzheimer's Disease BACE (β-site of APP cleaving enzyme) is a critical component in Alzheimer's Disease (AD), and the development of BACE inhibitors shows great potential as a therapy for the disease. BACE: Lead Target for Orchestrated Therapy of Alzheimer's Disease covers virtually all aspects of BACE from initial identification, discovery of inhibitors, and challenges in clinical development, while providing a global understanding essential for productive and successful drug discovery. This book details the story of the discovery of BACE and its role in AD and comprehensively discusses: The development of BACE inhibitors as therapeutics for Alzheimer's disease The research that led to the identification of BACE New BACE inhibitors currently being clinically tested ADME (absorption, distribution, metabolism, excretion) and clinical trial design—topics not addressed in current field literature Cutting-edge technology such as high-throughput screening, structure-based drug design, and QSAR in context of BACE inhibitors and Alzheimer's drug discovery Other approaches to BACE inhibition based on interaction with the precursor protein APP By enhancing the reader's understanding of the various aspects of the BACE drug-discovery process, this much-needed reference will serve as a key resource for all scientists involved in Alzheimer's research—and inspire new approaches to treatment of AD.

Cognitive Remediation Therapy For Schizophrenia

Author : Professor Til Wykes
ISBN : 9781135444099
Genre : Psychology
File Size : 49. 68 MB
Format : PDF, Kindle
Download : 364
Read : 1074

Download Now Read Online

Could CRT provide the first structured method of alleviating cognitive deficits associated with schizophrenia? Cognitive Remediation Therapy for Schizophrenia describes the background and development of this new psychological therapy and demonstrates how it provides the first structured help to overcome the thinking problems associated with schizophrenia. In three sections, the book covers the theoretical and empirical underpinning of cognitive remediation therapy and explores its application. Part I, 'The Development of Therapy', provides the historical context and theoretical background to the therapy and emphasizes the value of rehabilitating cognitive deficits. In Part II, 'Improving Cognitive Processes', the process and effects of changing cognition are examined. Finally, in Part III, 'The Process of Therapy', the authors provide a clinical guide to the delivery of cognitive remediation therapy and use case examples to support its efficacy. This book is the first to describe an individual cognitive remediation therapy programme based on a clear model of the relationship between thinking and behaviour. It will be of both academic and clinical value to all those health professionals and clinical academics who want not only to understand the relationships between thought and action but also to intervene to improve therapy.

Nutrient Power

Author : William Walsh
ISBN : 9781620872581
Genre : Health & Fitness
File Size : 85. 4 MB
Format : PDF, ePub, Docs
Download : 214
Read : 1144

Download Now Read Online

A veteran research scientist who has spent decades establishing biochemical treatment protocols for patients with ADHD, Alzheimer's disease and various mental disorders challenges popular opinions about psychiatric drugs to make recommendations for drug-free nutrient therapies that normalize the brain without producing serious side effects. 15,000 first printing.

Comprehensive Care Of Schizophrenia

Author : Jeffrey A. Lieberman
ISBN : 9780195388015
Genre : Medical
File Size : 50. 83 MB
Format : PDF, ePub
Download : 311
Read : 662

Download Now Read Online

The second edition of this popular volume has been thoroughly updated, offering new information on the advances in research and management since the publication of the first edition a decade ago.

Top Download:

New Books